|Closed||Metastatic Colorectal Cancer||Phase III||NCT01767857|
The purpose of this study is to determine if the True Human Monoclonal antibody MABp1 can prolong the life of colorectal carcinoma patients who are losing weight.
- Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy. To be considered refractory, a subject must have failed both an oxaliplatin and an irinotecan based regimen.
- Weight loss of ≥5% over the last 6 months.
- Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2.
- Palliative radiation and/or chemotherapy are permitted after the initial 2 week washout period.
- Mechanical obstruction that would prevent adequate oral nutritional intake.
- Serious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy.
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.